VistaGen Therapeutics to report first quarter fiscal 2023 financial results on August 11, 2022

SOUTH SAN FRANCISCO, California–(BUSINESS THREAD)–VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company that aims to transform the treatment landscape for people living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will host a conference call and a webcast on Thursday, August 11. 2022 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report financial results for the first quarter of fiscal year 2023 that ended June 30, 2022.

Event: VistaGen Therapeutics Q1 FY2023 Financial Results Conference Call

Date: Thursday, August 11, 2022

Time: 2:00 pm Pacific Time (5:00 pm Eastern Time)

Dialing in the US (toll free): 1-888-999-5318

International Toll/Toll: 1-848-280-6460

Conference ID: 4956626


An audio webcast of the conference will also be available via the link provided above. Participants must access this streaming website 10 minutes prior to the start of the call. In addition, a telephone replay of the call will be available beginning at approximately 5:00 p.m. Pacific Time on Thursday, August 11, 2022. To listen to the replay, call toll-free at 1-844-512-2921 at United States or 1 -412-317-6671 when calling internationally (toll). Please use Replay PIN 151563.

About VistaGen

VistaGen (Nasdaq: VTGN) is a late-stage clinical biopharmaceutical company striving to transform the treatment landscape for people living with anxiety, depression and other CNS disorders. The company is advancing drug candidates with the potential to act faster and with fewer side effects and safety issues than those currently available. VistaGen’s clinical-stage candidates target multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as ferin nasal sprays, which are investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can affect neural circuits of the olfactory amygdala without systemic systems. direct uptake or activity on CNS neurons in the brain. VistaGen is passionate about transforming mental health care and redefining what’s possible in the treatment of anxiety and depression. Connect to


Source link

You May Also Like

About the Author: Chaz Cutler

My name is Chasity. I love to follow the stock market and financial news!